All about FEET:

Autonomous_ID and USC Team Share 2018 Global Type 1 #Diabetes Innovation Award with Tech Designed to Prevent Amputations.BioSole is the new  technology to monitor the pressures of your foot. Autonomous_ID, a Canadian-American tech company and clinician researchers from the Keck School of Medicine of University of Southern California shared in an award focusing on global innovation in Diabetes. Their program, called “Smart Sole Salvation” won the Global People’s Choice Award. It is a combination of multiple technologies designed to foster improved activity while also identifying potentially limb-threatening complications of diabetes.  Read more:  BioSole and Autonomous_ID

BonBouton has developed a smart insole with a proprietary embedded graphene sensing system that passively monitors the skin’s physiological signals to detect early signs of foot ulcers in diabetic patients.  Read more: Bonbouton’s Smart Insole

 

Inhaled Vs. Injected Insulin was reported by Joy Pape and Arsalan Hashmi on DiabetesInControl.com, 20 October 2018. 

Despite today’s advances in diabetes medicine and technology, many people who have type 1 diabetes still have trouble managing their glucose levels, partly due to the mealtime insulins like Novolog, which may show peak levels up to 3 hours after injection.  Due to multiple physiological factors after injection of rapid-acting insulins, glucose levels may fluctuate from hyperglycemia to delayed hypoglycemia. Technosphere insulin (TI) is a dry-powder insulin that is inhaled, starts working in 12 minutes, and peaks in 35 to 45 minutes.  Read more:  Inhaled Vs. Injected Insulin

 

Diabeloop Obtains CE Marking for DBLG1 was reported by Jordan Dakin on BeyondType1.org, 11 November 2018.  Another closed loop system!!!

Image result for diabeloop

Diabeloop, a French medical technology company that specializes in creating accessible innovations for the Type 1 diabetes community, has obtained CE marking for its DBLG1TM System.  Conceived as a result of a research project on the artificial pancreas, the DBLG1TM System is a self-learning device that loops in AI technology to better serve diabetes patients. The device, worn externally, consists of a continuous glucose monitor (CGM, not yet described but looks like Dexcom), a patch insulin pump (CellNovo), and a smartphone type terminal that operates as a user interface.  Read more: Diabeloop Obtains CE Marking for DBLG1 and if you can read French: DiabeLoop France

 

The Senseonics Eversense CGM could Surprise & Delight Users as reported by Martin Hensel on InsulinNation.com, 8 November 2018.

Motivated patients who are tired of weekly and bi-weekly sensor insertions will not need much convincing. More importantly, those who are on CGM will see the value of long-term continuous glucose monitoring to help achieve or maintain their diabetes management goals while maintaining their active lifestyle. Besides the 3-month continuous use, the wearable transmitter can be taken off and on for those times you just don’t want anything on your body. The system can also alert you when you are low or about to go low – very useful especially during nighttime. You don’t have to carry a separate receiver as you use your own smartphone to see the results. And Eversense has outstanding accuracy with a MARD of 8.5% while providing the patient the freedom from self-insertions. Read more: Senseonics Eversense CGM

 

Quest to allow patients to order lab testing from home was reported by Conor Hale of FierceBiotech, 7 November 2018.  I think that is FABULOUS! 

Quest Diagnostics launched a direct-to-consumer service that allows users to order and pay for lab tests from home.

Dubbed QuestDirect, the online service offers 35 diagnostic test packages covering general health and wellness, men’s and women’s health, and the heart and digestive system, as well as panels for infections or sexually transmitted diseases.  To order, consumers select their own lab tests online—with independent physicians providing clinical oversight and ordering the testing—before making an appointment to visit a Quest patient service center for specimen collection.  Read more:  Quest to allow patients to order lab testing from home

 

Blood sugar control tied to long-term brain health with type 1 diabetes was reported by Carolyn Crist on Reuters.com, 5 October 2018. 

People with type 1 diabetes who are able to maintain good blood sugar control may reduce their long-term risk of developing dementia, a U.S. study suggests. Among more than 3,400 type 1 diabetes patients in a large healthcare system, those with average blood glucose readings near the normal range more than half of the time were 45 percent less likely to develop dementia than those whose readings were routinely higher, the study team reports in Diabetes Care.  Read more: Blood sugar control tied to long-term brain health with type 1 diabetes

 

What High Blood Sugar Feels Like was written by Jessica Apple on ASweetLife.org, October 2018.  And it is just so true!  Some great quotes by kids with T1 about how it feels when their blood sugars are high.

Well, it turns out, rage is an apt adjective, because when I reached out to the TypeOneGrit community to ask what high blood sugar feels like, many respondents said they get angry when high. Others said it feels like the flu, brain fog, body aches, sluggish, unable to focus, headache, exhausted, nauseated, slow death, like the life is being sucked out of them, and tearful. Mike Aviad, type 1 for 16 years, said he never eats sugar because, “I’ll enjoy myself for five minutes and then I’ll feel terrible for two days.”  Read more:  What High Blood Sugar Feels Like

 

All about Capillary Biomedical, a local southern California start-up developing technologies for diabetes management. CapBio’s kink-proof, super-soft cannula features multi-port delivery for reliable, and comfortable insulin delivery. User-friendly insertion makes it easy.

 

And if you make it this far in the blog, you deserve an interesting story! How llamas could help us fight the flu was reported on on Science/PBS.org, 1 November 2018. 

Last year’s flu season was the worst in decades, leading to more than 80,000 deaths in the U.S. alone. Vaccination is the most effective way to prevent the flu, but even as vaccines are made available around the world, mortality levels don’t seem to be decreasing. The World Health Organization attributes between 290,000 and 650,000 deaths to the seasonal flu each year.

Researchers now think they’re on the path to a new kind of flu protection—one that might last longer and work against all types of influenza viruses. The source of their new defense: llamas.

These furry South American mammals produce special antibodies—molecules that mark foreign invaders in our bodies for destruction— that can identify a huge range of elusive influenza viruses. A new study used these antibodies to target multiple strains of influenza at once, a technique that could lead to more effective flu prevention. These antibodies can survive without refrigeration for longer, which could reduce the cost and complexity of flu treatment.  Read more:  How llamas could help us fight the flu

 

Share This